This section of the website is used to post information about relevant clinical trials as we are made aware of them. At the Foundation, we recommend you ask your doctor whether there are any clinical trials going on that you may be able to join. This has two benefits: firstly, you will have the opportunity to try new drugs that, hopefully, will come on the market and which may help you; and secondly, you are contributing to important research and that will make you feel good.
If you become aware of a relevant clinical trial for pulmonary fibrosis patients, please contact us and will add it here.
Here are some of the exciting clinical trials that are currently enrolling that have been brought to our attention. You might like to check them out and discuss with your doctor. Currently only IPF-related clinical trials are recruiting in Canada.
To search for other clinical trials of interest to you, go to www.clinicaltrials.gov. Click on Show Study Locations to view the locations and any contact information.
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Sponsored by Boehringer Ingelheim –
|Hamilton, ON||Sarah Goodwinemail@example.com||(905) 521-6130|
|Halifax, NS||Scott Fultonfirstname.lastname@example.org||(902) 473-5653|
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis(IPF) (RAINIER)
Sponsored by Gilead Sciences — Simtuzumab is an antibody directed against human LOXL2. It is thought that LOXL2 may play a role in IPF. We are studying whether blocking his pathway may slow the progression of the disease.
Study Locations: Kelowna, BC; Vancouver, BC; Hamilton, ON: Toronto, ON; Montreal, QC, and Quebec City, QC. For contact information at each location, please go to the link above.
A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Sponsored by Hoffmann-La Roche — Lebrikizumab is an antibody that is dissolved in solution like water that can be injected under your skin. It attaches to interlukin-13 (IL-13); it is believed that IL-13 may play a role in IPF. The study is looking at whether blocking IL-13 will slow the progression of the disease.
Study Locations: Vancouver, BC; London, ON; Hamilton, ON; Ste. Foy, QC; and Moncton, NB. For Hamilton contact Sarah Goodwin email@example.com (905) 521-6130.
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults WithIdiopathic Pulmonary Fibrosis
Sponsored by MedImmune LLC.
Study Locations: Vancouver, BC; Edmonton, AB; Windsor, ON; Toronto, ON; Montreal, QC; and Quebec City, QC.